Key statistics
On Tuesday, Roche Holding AG (ROGN:MEX) closed at 6,067.00, -15.38% below its 52-week high of 7,169.32, set on Mar 04, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6,067.00 |
---|---|
High | 6,067.00 |
Low | 6,067.00 |
Bid | -- |
Offer | -- |
Previous close | 6,067.00 |
Average volume | 120.00 |
---|---|
Shares outstanding | 809.25m |
Free float | 724.70m |
P/E (TTM) | 25.26 |
Market cap | 212.58bn CHF |
EPS (TTM) | 10.32 CHF |
Annual div (ADY) | 224.54 MXN |
---|---|
Annual div yield (ADY) | 3.70% |
Div ex-date | Mar 28 2025 |
Div pay-date | Mar 31 2025 |
Data delayed at least 20 minutes, as of Jul 01 2025 12:30 BST.
More ▼
- Changes to the Roche Enlarged Corporate Executive Committee
- Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
- Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
- Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
- [Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
- Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)
- Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
- New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
- Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
- CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
More ▼